EMA Withdrawn: Zinbryta (daclizumab) — Biogen Idec Ltd

View source ↗

Summary

The EMA has withdrawn Zinbryta (daclizumab) from the market for multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Zinbryta (daclizumab high yield process)

Snippet

Status: Withdrawn. Therapeutic area: Multiple Sclerosis. MAH: Biogen Idec Ltd. Decision date: 27/03/2018